Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
Protagonist Therapeutics (Nasdaq:PTGX) announced that President and CEO Dinesh V. Patel, Ph.D., will participate in two June 2026 healthcare investment conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protagonist Therapeutics (Nasdaq:PTGX) announced that President and CEO Dinesh V. Patel, Ph.D., will participate in two June 2026 healthcare investment conferences.
He will join fireside chats at the Jefferies Global Healthcare Conference in New York on June 3 at 9:55 A.M. ET and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 10 at 9:20 A.M. ET, both accessible via webcast. Replay of the presentations will be available on the company’s investor relations website for one year.
Details
News Market Reaction – PTGX
On May 28, the day this news came out, PTGX closed 1.76% below the previous close.
Data tracked by StockTitan Argus for the May 28 session.
Key Figures
- Jefferies conference dates
- June 2–4, 2026
- Jefferies Global Healthcare Conference in New York, NY
- Jefferies session time
- June 3, 2026 at 9:55 A.M. ET
- Protagonist fireside chat schedule
- Goldman Sachs conference number
- 47th Annual
- Goldman Sachs Global Healthcare Conference 2026
- Goldman Sachs dates
- June 8–10, 2026
- Miami, FL healthcare conference
- Goldman Sachs session time
- June 10, 2026 at 9:20 A.M. ET
- Protagonist fireside chat schedule
- Replay availability
- One year
- Conference presentation replays on Investor Relations site
Historical Context
-
Profitable Q1 2026, ICOTYDE approval milestone and strong cash balance.
-
Rusfertide U.S. opt-out, large milestone potential and high-tier royalties.
-
Stock option and RSU grants for new hires under inducement plan.
-
U.S. FDA approval of ICOTYDE for plaque psoriasis with milestone and royalties.
-
FDA acceptance and Priority Review of rusfertide NDA for polycythemia vera.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in two investment bank conferences taking place in June 2026.
2026 Jefferies Global Healthcare Conference; New York, NY - June 2-4, 2026
Format: Fireside Chat
Day/Time: Wednesday, June 3 at 9:55 A.M. ET
Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/STGS2oumT8ZPxxrEhwVAR5
Goldman Sachs 47th Annual Global Healthcare Conference 2026; Miami, FL - June 8-10, 2026
Format: Fireside Chat
Day/Time: Wednesday, June 10 at 9:20 A.M. ET
Webcast: https://event.webcasts.com/starthere.jsp?ei=1764366&tp_key=bf1c052870&tp_special=8
If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative.
A replay of the presentations will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.